Nicole  Barna net worth and biography

Nicole Barna Biography and Net Worth

Insider of Codiak BioSciences
Nicole Barna brings over 20 years of experience in human resources leadership and strategy. Prior to her current leadership role, Ms. Barna was Executive Director for Human Resources at Bioverativ where she led Bioverativ’s efforts in talent management, performance management, leadership development and global expansion. Ms. Barna was also instrumental in the creation of Bioverativ, a spin-off from Biogen, where she was responsible for organizational design and talent identification. Prior to Bioverativ, Ms. Barna held a number of positions of increasing responsibility and scope at Biogen, including Sr Director Human Resources for Emerging Markets and Latin America, Director of HR for the Japan Affiliate, Director of HR for UK/Ireland Affiliates and various positions in the US supporting the R&D organization. Prior to Biogen, she spent seven years at The Whitehead Institute/ Center for Genome Research where she held HR positions of increasing responsibility including leading HR for the team responsible for the Human Genome Project. Ms. Barna holds an MS in HR Management from Lesley University and a BS in Psychology from Kenyon College.

How old is Nicole Barna?

Ms. Barna is currently 48 years old. There are 6 older executives and no younger executives at Codiak BioSciences. The oldest executive at Codiak BioSciences is Dr. Douglas Edward Williams Ph.D., Pres, CEO & Director, who is 64 years old. Learn More on Nicole Barna's age.

How do I contact Nicole Barna?

The corporate mailing address for Ms. Barna and other Codiak BioSciences executives is , , . Codiak BioSciences can also be reached via phone at 617-949-4100 and via email at [email protected]. Learn More on Nicole Barna's contact information.

Has Nicole Barna been buying or selling shares of Codiak BioSciences?

Nicole Barna has not been actively trading shares of Codiak BioSciences within the last three months. Most recently, on Thursday, January 20th, Nicole Barna bought 6,781 shares of Codiak BioSciences stock. The stock was acquired at an average cost of $7.37 per share, with a total value of $49,975.97. Learn More on Nicole Barna's trading history.

Who are Codiak BioSciences' active insiders?

Codiak BioSciences' insider roster includes Nicole Barna (Insider), Konstantin Konstantinov (CTO), Sriram Sathyanarayanan (Insider), and Benny Sorensen (Insider). Learn More on Codiak BioSciences' active insiders.

Are insiders buying or selling shares of Codiak BioSciences?

During the last twelve months, insiders at the sold shares 4 times. They sold a total of 66,071 shares worth more than $11,978.50. The most recent insider tranaction occured on March, 30th when insider Yalonda Howze sold 1,628 shares worth more than $325.60. Insiders at Codiak BioSciences own 8.2% of the company. Learn More about insider trades at Codiak BioSciences.

Information on this page was last updated on 3/30/2023.

Nicole Barna Insider Trading History at Codiak BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/20/2022Buy6,781$7.37$49,975.97View SEC Filing Icon  
See Full Table

Nicole Barna Buying and Selling Activity at Codiak BioSciences

This chart shows Nicole Barna's buying and selling at Codiak BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Codiak BioSciences Company Overview

Codiak BioSciences logo
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00
Low: $0.05
High: $6.98

Volume

N/A

Average Volume

1,366,845 shs

Market Capitalization

$58,928.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.71